Chronic non-cancer pain and the long-term efficacy and safety of opioids: Some blind men and an elephant?☆
► Chronic opioid therapy is useful for selected patients with chronic non-cancer pain (CNCP). ► This approach can be safe and effective for many years. ► For some patients high doses are required. ► Adverse effects (drowsiness and constipation) were not major problems due to either tolerance or selection. ► Careful screening regarding such issues as appropriate CNCP disorders and addiction risk, documentation and follow-up are critical.
Abstract
Background
The use of opioids for chronic non-cancer pain (CNCP) remains very controversial. There are a number of randomized controlled trials (RCTs) showing efficacy and safety in the short-term, but long-term data are limited.
Methods
This article contains 10 case reports (followed to 2011) that were selected from a survey of 84 patients with intractable CNCP treated with opioids and followed every 3 months now for a median of 10 years. The previous published survey of this group reported outcomes of pain severity, adverse effects, pain relief, satisfaction, mood, problematic opioid use, tolerance, physical dependency, functional status, health-related quality of life (HRQL), immune status and sexual function. The outcome measures for that study included a numerical rating scale (NRS) for pain, Hospital Anxiety and Depression Scale (HADS), the Brief Pain Inventory Interference Scale (BPI-I), the Pain Disability Index (PDI), and for Health Related Quality of Life (HRQL) the Short Form Health Survey 12 version 2 (SF12v2). These selected patient reports were chosen to illustrate some important aspects of the diagnostic categories of CNCP, the opioids and doses used, particular issues (concurrent addiction history, bipolar disorder, and combination therapy), disease-specific and other outcomes (pain severity and relief, adverse effects, mood, function) and duration of follow-up with complex pain problems.
Results
Opioids were found to be safe and effective in the long-term for these particular patients, as well as in the larger group from which they originate. Most patients in the total sample reported 50% or greater relief and a moderate improvement in disability. Scores for functional status and HRQL were not severely affected (PDI and BPI-I ratings moderate or less and SF12v2 slightly below normative values for age). Problematic use, tolerance, and serious adverse effects including constipation were not major issues.
Conclusion
These 10 reports of patients with intractable CNCP treated with opioids with some success over many years put a face on some of the participants in the larger survey of 84 suggesting that this approach is effective and safe for some patients over many years.
Implications
These data may not be generalizable to a larger population of patients with CNCP because of the probable selection of patients who benefit and who do not have intolerable adverse effects.
Keywords: Chronic non-cancer pain, Opioids, Long-term safety and efficacy
☆ Updated text and illustrations from presentations at the International Neuropathic Pain meeting in Berlin in 2007 and at the Scandinavian Association of Anesthesia and Intensive Care 30th Congress meeting in Odense, Denmark in 2009.
PII: S1877-8860(11)00140-6
doi:10.1016/j.sjpain.2011.11.001
© 2011 Scandinavian Association for the Study of Pain. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Keeping an open mind: Achieving balance between too liberal and too restrictive prescription of opioids for chronic non-cancer pain: Using a two-edged sword
